Login / Signup

Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg).

Olga P NyssenAngeles Perez-AisaLuis RodrigoManuel CastroPilar Mata RomeroJuan OrtuñoJesus BarrioJose Maria HuguetInes ModollelNoelia AlcaideAlfredo LucendoXavier CalvetMonica PeronaBarbara GomezBlas Jose Gomez RodriguezPilar VarelaManuel Jimenez-MorenoManuel Dominguez-CajalLiliana PozzatiDiego BurgosLuis BujandaJenifer HinojosaJavier Molina-InfanteTommaso Di MairaLuis FerrerLuis Fernández-SalazarAriadna FiguerolaLlucia TitoCristobal de la CobaJudith Gomez-CamareroNuria FernandezMaria CaldasAna GarreElena ResinaIgnasi PuigColm O'MorainFrancis MégraudFrancisco Javier García-Alonso
Published in: Helicobacter (2020)
Third-line H pylori eradication with bismuth quadruple treatment (after failure with clarithromycin and levofloxacin) offers acceptable efficacy and safety. Highest efficacy was found in compliant patients and those taking 10-day BQT-three-in-one or 14-day BQT-Tet. Doxycycline seems to be less effective and therefore should not be recommended.
Keyphrases
  • helicobacter pylori infection
  • helicobacter pylori
  • end stage renal disease
  • newly diagnosed
  • chronic kidney disease
  • peritoneal dialysis
  • prognostic factors
  • big data
  • machine learning